|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.538 EUR | +0.26% |
|
-1.16% | -4.00% |
| 07-21 | Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502 | CI |
| 07-21 | Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +0.26% | -1.16% | -10.06% | +21.29% | -4.00% | -15.96% | -43.14% | -46.37% | -85.97% | 166M | |
| +1.21% | -0.53% | -2.27% | +14.91% | +5.47% | +4.00% | +15.71% | -19.80% | +205.93% | 48.57B | |
| +1.98% | +9.05% | +4.26% | +34.03% | +147.71% | +413.94% | +532.17% | +598.65% | - | 41.95B | |
| +3.44% | -4.65% | +14.01% | +33.80% | +4.72% | +28.34% | +8.81% | -4.98% | +203.48% | 38.85B | |
| +1.40% | +0.10% | +10.04% | +10.10% | +7.81% | +6.61% | +61.93% | -2.49% | +1,136.43% | 37.24B | |
| +2.42% | +5.72% | +3.65% | +1.02% | +10.40% | +12.38% | +44.79% | -13.95% | +160.90% | 30.67B | |
| -0.16% | -3.11% | -11.04% | +8.40% | - | - | - | - | - | 16.1B | |
| +2.20% | +0.48% | +5.41% | +36.58% | +4.65% | +34.71% | +127.15% | +226.26% | - | 16.41B | |
| +0.75% | +2.30% | +2.15% | +16.97% | +12.47% | +8.64% | +19.52% | -37.75% | +84.61% | 13.97B | |
| +4.25% | -8.23% | -5.52% | +34.78% | -10.27% | -1.49% | -35.46% | -32.86% | +113.91% | 12.62B | |
| +11.36% | +11.04% | +13.02% | +40.63% | +30.70% | +55.66% | +26.01% | -36.41% | +204.15% | 12.56B | |
| -0.12% | -0.04% | +1.65% | +27.03% | +22.43% | +31.77% | -12.38% | -41.30% | +155.73% | 11.22B | |
| +0.55% | +1.11% | -14.90% | -0.45% | -8.89% | +78.96% | +565.66% | +297.46% | +2,365.17% | 10.86B | |
| +0.03% | +0.02% | +0.99% | +61.16% | +77.84% | +250.20% | +548.45% | - | - | 10.08B | |
| +0.10% | +7.36% | +35.14% | +36.34% | +40.56% | +34.05% | +36.06% | -61.52% | - | 9.86B | |
| -1.60% | +0.28% | -33.75% | -27.99% | -31.50% | +25.88% | +36.36% | +37.61% | +50.03% | 9.01B | |
| -0.90% | +0.33% | +4.61% | +23.38% | -11.38% | -20.22% | -17.62% | -28.77% | +34.29% | 8.68B | |
| +1.11% | +3.25% | +4.33% | +38.41% | +57.22% | +154.77% | +615.95% | +184.96% | - | 8.83B | |
| +2.95% | +9.69% | +0.22% | -4.22% | +8.31% | +567.98% | +2,116.88% | +44.48% | - | 8.9B | |
| +1.04% | +0.22% | -7.07% | +27.53% | +35.56% | +145.47% | +367.35% | +69.39% | - | 8.68B | |
| Average | +1.62% | +1.33% | +0.74% | +21.68% | +21.04% | +95.56% | +263.90% | +62.92% | +385.72% | 17.76B | |
| Weighted average by Cap. | +1.89% | +0.97% | +2.98% | +21.29% | +28.33% | +95.74% | +203.09% | +93.07% | +420.27% |
- Stock Market
- Stocks
- IPH Stock
- Sector Innate Pharma
Select your edition
All financial news and data tailored to specific country editions
